LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis
Shots:
- The P-III ECZTRA 6 trial evaluates the efficacy & safety of tralokinumab (150/300mg- q2w) as monothx. vs PBO in 301 patients aged 12-17yrs. with mod. to sev. AD who were candidates for systemic therapy
- The trial met its 1EPs & 2EPs i.e.- @16wks.- patients achieved a clinical response & achieved clear or almost clear skin as measured by IGA (21.4%/17.5% vs 4.3%); ≥75% disease improvement from baseline (28.6%/27.8% vs 6.4%) as measured by EASI
- In 2EPs- patients achieved 4-point improvement in adolescent weekly average worst daily pruritus NRS score & health-related QoL related to dermatological conditions. The therapy was well-tolerated with an overall frequency & severity of AEs
| Ref: Businesswire | Image: Berlingske
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com